Drugs in the COVID-19 pandemic: Analysis of the commercialization of azithromycin, hydroxychloroquine, ivermectin and nitazoxanide in Brazil
Keywords:COVID-19; SARS-CoV-2 infection; Pandemic by COVID-19; Prescription drug misuse; Brazil.
The coronavirus infection (COVID-19) has affected more than 22 million Brazilians, causing more than 600,000 deaths Until the vaccines were available, there was an intense search in Brazil for promising candidate drugs for the treatment of the disease, including antibiotics, antimalarials, antiparasitics and immunosuppressive agents. Despite intense investigations, there are still no safe and effective drugs based on scientific evidence against this virus. The objective of this study was to evaluate the impact of the marketing of drugs azithromycin, hydroxychloroquine, ivermectin and nitazoxanide in Brazil during the COVID-19 pandemic period of 2020. Data on the marketing of drugs were taken from the National Controlled Products Management System (SNGPC). The results showed that among the drugs investigated, azithromycin was the most marketed in the country, followed by hydroxychloroquine, ivermectin and nitazoxanide. The Brazilian region with the highest consumption of these drugs was the Southeast, followed by the South, Northeast, Midwest and North. From the information analyzed in the study, we concluded that there was a potential consumption in Brazil of the investigated drugs, especially azithromycin. These data serve as a warning for the elaboration of future public strategies that adequately educate the population and health professionals about the risks of using drugs without safety and proven efficacy against COVID-19.
Abbott Laboratórios do Brasil Ltda. Bula do paciente Revectina (ivermectina). (2021). https://dam.abbott.com/pt-br/documents/pdfs/nossas-bulas/r/BU-15-Revectina-bulade
Adebisi, Y. A., Jimoh, N. D., Ogunkola, I. O., Uwizeyimana, T., Olayemi, A. H., Ukor, N. A., & Lucero-Prisno, D. E., 3rd (2021). The use of antibiotics in COVID-19 management: a rapid review of national treatment guidelines in 10 African countries. Tropical medicine and health, 49(1), 51.
Agência Nacional de Vigilância Sanitária (2017). Plano Nacional para a Prevenção e o Controle da Resistência Microbiana nos Serviços de Saúde. http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=m6vpZEgtbjw%3D.
Alves L. (2021). Brazilian ICUs short of drugs and beds amid COVID-19 surge. Lancet (London, England), 397(10283), 1431–1432.
Alves Neto, U.E., Pires, A.C. (2020) Drogas e medicamentos investigados para o tratamento do COVID-19 J. Health Biol. Sci. (Online); 8(1):1-7.
Amadi, B., Mwiya, M., Musuku, J., Watuka, A., Sianongo, S., Ayoub, A., & Kelly, P. (2002). Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet (London, England), 360(9343), 1375–1380.
ANVISA (2020). Estabelecido controle de medicamentos durante pandemia. Disponível em: http://antigo.anvisa.gov.br/resultado-de-busca?p_p_id=101&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&_101_struts_action=%2Fasset_publisher%2Fview_content&_101_returnToFullPageURL=http%3A%2F%2Fantigo.anvisa.gov.br%2Fresultado-de-busca%3Fp_auth%3D1sVB92TX%26p_p_id%3D3%26p_p_lifecycle%3D1%26p_p_state%3Dnormal%26p_p_state_rcv%3D1&_101_assetEntryId=5956620&_101_type=content&_101_groupId=219201&_101_urlTitle=estabelecido-controle-de-medicamentos-durante-pandemia&inheritRedirect=true.
Ayres, M. & Jr, M. & Ayres, D.L. & Dos Santos, Alex De Assis. (2007). BIOESTAT – aplicações estatísticas nas áreas das Ciências Bio-Médicas.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral research, 178, 104787
Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S. C., & Di Napoli, R. (2021). Features, Evaluation, and Treatment of Coronavirus (COVID-19). In StatPearls. StatPearls Publishing.
Chauhan, V., & Thakur, S. (2021). State of the Globe: The Frenzy of Self-Medication, Cocktail Regimens and Everchanging Guidelines on SARS-CoV-2. Journal of global infectious diseases, 13(2), 65–66.
Coronavirus disease (COVID-19) Pandemic: World Health Organization World Health Organization, Geneva, Switzerland (2020) https://www.who.int/emergencies/diseases/novel-coronavirus-2019
ECOVERY Collaborative Group (2021). Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (London, England), 397(10274), 605–612. https://doi.org/10.1016/S0140-6736(21)00149-5
Fiolet, T., Guihur, A., Rebeaud, M. E., Mulot, M., Peiffer-Smadja, N., & Mahamat-Saleh, Y. (2021). Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 27(1), 19–27.
Food and Drug Administration. FDA Consumer Updates: Why You Should Not Use Ivermectin to Treat or Prevent COVID-19. https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19
Galvão, Izabelli Cristiane da Silva. (2021). Resistência bacteriana: uma investigação genômica baseada em mecanismos de resistência contra a azitromicina (2019-2021). Trabalho de Conclusão de Curso. Universidade Federal do Rio Grande do Norte.
Imperador, C. H. L., Espreafico Junior, C. R., Nascimento Antonio, M. V., Chin, C. M., & Bosquesi, P.L. (2020). Cloroquina e hidroxicloroquina associado ao zinco e/ou azitromicina na COVID-19. Ulakes journal of medicine, v. 1: Edição Especial Covid-19.
Johns Hopkins Coronavirus Resource Center, 2021. COVID-19 Map. https://coronavirus.jhu.edu/map.html.
Kramer, D. G., Cavalcanti Junior, G. B., & Pereira, N. de S. (2020). Hidroxicloroquina: uso potencial em coronaviroses? Revista Contexto &Amp; Saúde, 20(38), 16–21.
Langford, B. J., So, M., Raybardhan, S., Leung, V., Soucy, J. R., Westwood, D., Daneman, N., & MacFadden, D. R. (2021). Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 27(4), 520–531.
Malik, M., Tahir, M. J., Jabbar, R., Ahmed, A., & Hussain, R. (2020). Self-medication during Covid-19 pandemic: challenges and opportunities. Drugs & therapy perspectives: for rational drug selection and use, 1–3. Advance online publication.
Marcolino, M. S., Ziegelmann, P. K., Souza-Silva, M. V., Nascimento, I. J. B., Oliveira, L. M., Monteiro, L. S., & dos Santos, V. B. (2021). Clinical characteristics and outcomes of patients hospitalized with COVID-19 in Brazil: Results from the Brazilian COVID-19 registry. International Journal of Infectious Diseases, 107, 300-310.
Melo, J.R.R., Duart, E.C., Moraes, M.V., Fleck, K., Arrais, P.S.D. (2021). Automedicação e uso indiscriminado de medicamentos durante a pandemia da COVID-19. Cad. Saúde Pública 2021; 37(4):e00053221.
Ministério da Saúde (2021). Azitromicina para o tratamento de pacientes com COVID-19. https://www.gov.br/saude/pt-br/coronavirus/publicacoes-tecnicas/notas-tecnicas/nota-tecnica-azitromicina-covid-19.
National Institutes of Health COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/
Peña-Silva, R., Duffull, S. B., Steer, A. C., Jaramillo-Rincon, S. X., Gwee, A., & Zhu, X. (2021). Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19. British journal of clinical pharmacology, 87(3), 1589–1590.
Rocco, P., Silva, P. L., Cruz, F. F., Melo-Junior, M., Tierno, P., Moura, M. A., De Oliveira, L., Lima, C. C., Dos Santos, E. A., Junior, W. F., Fernandes, A., Franchini, K. G., Magri, E., de Moraes, N. F., Gonçalves, J., Carbonieri, M. N., Dos Santos, I. S., Paes, N. F., Maciel, P., Rocha, R. P., SARITA-2 investigators (2021). Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. The European respiratory journal, 58(1), 2003725.
Ruiz J. (2021). Enhanced antibiotic resistance as a collateral COVID-19 pandemic effect? The Journal of hospital infection, 107, 114–115.
Santos, J. R.M., Monteiro, L., Sousa, S.G., Araújo, B.G. (2021). The risks of hydroxychlorochine self-medication in front of the COVID-19 Pandemic. Brazilian Journal of Health Review, 4 (3), 11185-11204.
Sen-Crowe, B., McKenney, M., & Elkbuli, A. (2021). Medication shortages during the COVID-19 pandemic: Saving more than COVID lives. The American journal of emergency medicine, 45, 557–559.
Sociedade Brasileira de Bioética, 2020. SBB solicita revogação imediata da orientação do Ministério da Saúde sobre uso da cloroquina em pacientes com COVID-19. https://www.sbbioetica.org.br/Noticia/777/NOTA-PUBLICA-SBB-solicita-revogacao-imediata-da-orientacao-do-Ministerio-da-Saude-sobre-uso-da-cloroquina-em-pacientes-com-COVID-19.
Vallejos, J., Zoni, R., Bangher, M., Villamandos, S., Bobadilla, A., Plano, F., Campias, C., Chaparro Campias, E., Medina, M. F., Achinelli, F., Guglielmone, H. A., Ojeda, J., Farizano Salazar, D., Andino, G., Kawerin, P., Dellamea, S., Aquino, A. C., Flores, V., Martemucci, C. N., Martinez, S. M., & Aguirre, M. G. (2021). Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. BMC infectious diseases, 21(1), 635.
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research, 30(3), 269–271.
WHO (2020). Recommends against the use of remdesivir in COVID-19 patients: World Health Organization. https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients.
Yazdany, J., & Kim, A. (2020). Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. Annals of internal medicine, 172(11), 754–755.
How to Cite
Copyright (c) 2022 Marcia Mayanne Almeida Bezerra; Icaro Natan da Silva Moraes; Ana Luiza de Oliveira Barboza; Emilly Santana da Silva; Erika Cristina de Oliveira Cardoso; Giovanna Sayuri Xavier Moraes de Oliveira; Izadora Martins Coelho; Leonardo Wanzeller Magalhaes; Lohrane Costa Campos Gomes; Maurício Ferreira Gomes; Adonis de Melo Lima; Luiz Mário Pará Rodrigues; Clebson Pantoja Pimentel; Silvan Francisco da Silva; Darlen Cardoso de Carvalho
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.